We have successfully supported nearly 100 anti-infection clinical projects, including INDs, NDAs, and global multicenter trials across early and late development stages.
Our expertise spans a wide range of agents, including:
Antibiotics (e.g., carbapenems, cephalosporins, tetracyclines, macrolides)
Antivirals and vaccines, including pandemic-response products
Antifungals, antituberculosis drugs, and antiparasitic agents
Our anti-infection clinical service model includes:
WHO-aligned clinical strategies and regulatory documentation
Flexible trial designs and rapid-response operational frameworks
Accelerated project timelines, even under high-pressure outbreak conditions
Experienced clinical teams providing continuous scientific and regulatory support
Whether you're launching a novel antiviral, preparing for WHO PQ submission, or scaling a vaccine trial globally, GCP ClinPlus delivers the infrastructure, expertise, and urgency to bring your anti-infective innovations to patients faster and safer.